UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2026

@ BERHL DRUGS LIMITED Regd. Off.: 29, Neer Nagar, "Mayank Water Park Road", Bicholi Hapsi, INDORE-452016 (M.P.) INDIA Tel. : (0731) 2517677 | E-mail : beryldrugs25@yahoo.com | CIN : L02423MP1993PLC007840 Date: 11.08.2026 The Secretary, Department of Corporate Services, Bombay Stock Exchange Limited (BSE), Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai — 400001 Scrip Code: 524606 Sub.: Disclosure of Regulation 30 read with Part- A of Schedule il of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Dear Sirs, Pursuant to Regulation 30 read with Part- A of Schedule IIl of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform that the Board of Directors in its 4/2026-2027 Board Meeting held on 11.08.2026 has approved the Unaudited Financial Results of the Company for the Quarter ended 30.06.2026. We hereby request you to kindly acknowledge the receipts of same. Thanking You, Yours Sincerely ’g‘“"fl 4 BERYL DRUGS LIMITED 29, Neer Nagar, Mayank Water Park Road, Bicholi Hapsi Indore - 452 016. Tel Fax 0731-2517677 E-mail : beryldrugs25@yahoo.com ANNEXURET Submission of Unaudited/ Audited Financial Result by Companies Other than Banks Part] (R In Lakhs) except per share data| Statement of Unaudited Result for the Quarter ended 30106/2026 T Quarter ended Year ended 3months ended _|Preceding 3 months [Corresponding 3 |Previous year (30-06-2026) ended months ended in the [ended Particulars (31-03-2026) previous year (31-03-2026) (30-06-2025) (Refer Notes Below) Unaudited Audited Unaudited Audiied 1 [Revenue From Operations Net sales or Revenue from Operations 729.67) 51291] 479.43] 1882.01] Other operating revenues 2696 33.83 415 49.00) Total Revenue from operations (net) 756.63 546.74] 283.58) 1931.02 2 [Expenses (a)_|Cost of materials consumed 433.99 343.03] 22087 1050.99 (6)_[Purchases of stock-in-trade 0.00 0.00 0.00 0.00 (c)_|Changes in inventories of finished goods, work-in-progress and stock-in-trade 899 30,69 1839 7432 (d)_[Employee benefit expense 6313 62.90] 53.39 252.88] (e)_[Finance costs 6.20) 7.15 10.09 3443 (| Depreciation and amortisation expense 3160 40.26| 38.08 149.3)] (g)_|Other Expenses 185.74 37.51] 17257 458.92] Total expenses 729.65] 60,16 476.61 1872.22] 3 Profit (loss) from operations before exceptional items and tax] 26.98 86.58] 6.97 58.80) 7_|Exceptional items 0.00 0.00 0.00 0.00) 5 Profit (loss) before tax 26.98] 86.58] 6.97] 58.80] 6 _|TaxExpense Current tax 137] 3.43 15.00) 10.69) [Adjustments in respect of current income tax of proir year 0.00 0.00 0.00 0.69) Deferred tax 3.58) 26.90) -10.14) 4.94 Total Tax Expanses 4.90 3033] 4.86) 16.32] 7| Net Profit (loss) for the period from continuing operations 22.08 56.25 2.11] 4248 & _|Net Profit (loss) from discontinuing operations before tax 0.00 0.00] 0.00] 0.00 s [Tax Expense of discontinuing operations 0.00 0.00 0.00 0.00 10| Net Profit (loss) from discontining operations after tax 0.00) 0.00] 0.00) 0.00) 1 Net Profit (loss) for the Period 22.08 56.25) 2.11] 42.48] 12_|Other comprehensive income tems that will not be reclassified to proofr ilotss 068 211 0.24] 181 items that will be reclassified to profit or loss 0.00 Total Other Comprehensive Income 0.68 211 0.24] -181] 5] Total Comprehensive Income| 22.76] 54.14] 235 3067 14_|Detalls of equity share captal Paid-up equity share capital 507.17] 507.17] 507.17] 507.17] Face value of equity share capital 10.00] 10.00] 10.00) 10,00 15_[Earnings per share (of Rs. 10 each)- for continuing operations i |Basic 0.47] 111 0.04] 0,84 ii_[Diluted 0.3 111 004 0.89 1. The above financial resuls have been prepared in accordance with the recogition and mesurement pinciples sated therein prescribed under Section 133 of the Companies Act, 2013 read with elevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 oft h Liting Agreement Regulation 2. The above resultsfor the quarter ended 301h June 2026 which have been subjected to Limited Review by Statutory Auditors o the Company were reviewed and recommended by the Audit Comitice and subsequently by the Board of Directors at its meeting held on 11th August, 2026 i terms of regulaton 33 of SEBI (Listng Obligations and Disclosure Requirements) , Regultion, 2015, as amended 3. The Income from Operations s from one segment namely "Pharmaceutical Industry” as per Ind AS 108" Operating Segments” 4 The figures for the quarter ended March 31, 2026 are balancing figures between audited fiures i respect of full financial year ended March 31, 2026 and the unaudited published figure up to December 31, 2026 being the end oft hird quarter of the inancial year which were subjected to limited review: 5. The figuresfor the previous periods have been regrouped! reclassified. wherever necessary (o confim to current period classification 6. Depreciation s provided on Written down value method on the estimated remaining usefullives of the assets 7. Revenue from Operations is net of GST 8. Eamings per Share amount is Shown in Rupees. Place Indore Date : 11.08.2026 Subhash Chand Jain Anurag & Associates Chartered Accountants 104, Archana Apartment, 8-B, Ratlam Kothi, Indore-452001 (MP) PH # 2519439, 2527682 FAX# 0731 2519116 INDIA Mob. No.: +91-9302123882 Email: scjainca2004@yahoo.com Independent Auditor's Review Report on Unaudited Quarterly Financial Results and Year.to Date Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) The Board of Directors Beryl Drugs Limited 29, Neer Nagar, Mayank Water Park Road, Bicholi Mardana, Indore Madhya Pradesh-452016 1. We have reviewed the accompanying statement of unaudited financial results of Beryl Drugs Limited ("the Company") for the quarter ended June 30, 2026 ("the Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 and Regulation 52 of the SEBI (Listing Obligations and’ Disclosure Requirements) Regulation, 2015, as amended (the "Listing Regulations'}. 2. This Statement is the responsibility of the Company's Management and has been " approved by the Board of Directors and prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" (Ind AS 34) prescribed under section 133 of the Companies Act, 2013 read with rule 3 of Companies (Indian Accounting Standard) rules 2015, as amended read with relevant rules issued there under and other accounting principles generally accepted in India. Qur responsibility is to express a conclusion on the Statement based on our review. 3. We conducted our review of the statement in accordance with the Standard on Review Engagement (SRE) 2410,"Review of Interim Financial Information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim flnam:lal mformatlon consist of making mqumes prlmarlly of accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. 4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33, Regulation52 and Regulation 54 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, [Showing first 8,000 characters — download PDF for full document]